8-K ·Filed Jun 4, 2026

CHRN

ChronoScale Corp
BEARISH
Impact 6/10
Horizonweeks Processed4mo ago SEC0001493152-26-027271
8-K material event: Items 2.05
Actionable Insight ▼ Bearish

The divestiture of Ekso Bionics represents a strategic pivot to cloud-only operations, but the lack of cost estimates and the material charges create near-term uncertainty. Watch for the amendment with charge estimates within 4 business days — if charges are large relative to the $68M market cap, the stock could face further pressure. Monitor for any sale price disclosure to gauge recovery value.

DirectionBearish
Confidencemedium
Horizonweeks
Final — all horizons settled through T+60d
CHRN ▼ -4.47% at T+60d
SHORT call ✓ call won +4.47% · α vs SPY +8.47% · entry $19.03 → $18.18
Entry anchored
Jun 4, 2026
via day open
T+1d
-0.74%
call +0.74% · α +0.96%
$18.89
settled 4mo ago
T+5d
-3.52%
call +3.52% · α +4.09%
$18.36
settled 4mo ago
T+20d
-4.10%
call +4.10% · α +5.96%
$18.25
settled 3mo ago
T+60d
-4.47%
call +4.47% · α +8.47%
$18.18
settled 5w ago

Price Chart

Loading chart...

Executive Summary

ChronoScale Corp's board committed to divest its wholly owned subsidiary Ekso Bionics to focus solely on its cloud business. The company expects material charges including severance, lease termination, and transaction costs but has not yet estimated the total amount. The divestiture is expected to close in the first fiscal quarter.

Key Facts

  • Board committed to divest Ekso Bionics on May 29, 2026
  • Company will focus operations solely on its cloud business
  • Expects material charges: severance, lease termination, transaction expenses
  • No good-faith estimate of total charges yet; amendment to follow within 4 business days of determination
  • Divestiture expected to complete during the first fiscal quarter

Financial Impact

Material charges expected but not yet quantified; includes severance, lease termination, and transaction costs

revenueoperating incomecash flow

Risk Factors

  • Divestiture costs may be material and exceed market expectations
  • Execution risk in completing the sale or wind-down of Ekso
  • Revenue loss from Ekso without clear cloud business growth trajectory

Market Snapshot

Exchange
Nasdaq
Analyst Consensus
75% bullish (8 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-027271
Document: 0001493152-26-027271-index-headers.html0001493152-26-027271
Document: 0001493152-26-027271-index.html0001493152-26-027271
Document: 0001493152-26-027271.txt0001493152-26-027271
6 reports for CHRN
Performance horizon
Filters
Rows
Reports for CHRN — sortable, filterable
TypeNow
Aug 18, 2026
6w ago
8-K
NEUTRAL ★ 2/10
$23.70 $20.13▼ −15.06%▼ −13.11%$19.21 (−18.95%)
Jul 16, 2026
11w ago
EFFECT
NEUTRAL ★ 3/10
$25.71 $20.62▼ −19.80%▼ −23.42%$19.21 (−25.28%)
Jun 30, 2026
13w ago
S-3
NEUTRAL ★ 4/10
$17.64 $18.52▲ +4.99%▲ +7.17%$19.21 (+8.90%)
Jun 30, 2026
13w ago
8-K
NEUTRAL ★ 3/10
$17.64 $18.52▲ +4.99%▲ +7.17%$19.21 (+8.90%)
Jun 26, 2026
14w ago
8-K
NEUTRAL ★ 4/10
$22.86 $21.50▼ −5.95%▼ −5.67%$19.21 (−15.97%)
Jun 4, 2026
17w ago
8-K
BEARISH ★ 6/10
$19.03 $18.25▲ +4.10%▲ +5.96%$19.21 (−0.95%)
Showing 6 of 6

US Market Status

Market Closed — Opens Mon (64h 36m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access